Literature DB >> 20141388

An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome.

Dorte Glintborg1, Marianne Andersen.   

Abstract

Hirsutism is a common endocrine disorder, defined as increased growth of terminal hairs in a male pattern. Hirsutism is most often caused by polycystic ovary syndrome (PCOS), whereas only 5% patients are diagnosed with rare endocrine diseases. PCOS may be considered a multiorgan disease causing not only increased adrenal and ovarian sex hormone secretion but also changed secretion of gonadotrophins, growth hormone, and adrenocorticotrophic hormone (ACTH) from the pituitary. The majority of patients with PCOS are insulin resistant and PCOS is characterized by an increased inflammatory state with abdominal obesity and increased secretion of interleukins, chemokines, and adipokines. PCOS is therefore associated with an increased risk of the metabolic syndrome and type 2 diabetes (T2D). Patients with hirsutism present with increased bone mineral density despite decreased D-vitamin levels. The etiology to hirsutism and PCOS is most likely multifactorial including both genetic and environmental factors such as increased fetal stress and intrauterine growth retardation. In the present review, we give a comprehensive overview of the pathophysiology and multiple endocrine disturbances of hirsutism and PCOS.

Entities:  

Mesh:

Year:  2010        PMID: 20141388     DOI: 10.3109/09513590903247873

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  32 in total

1.  Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study.

Authors:  Hsin-Yi Yang; Herng-Sheng Lee; Wan-Ting Huang; Ming-Jer Chen; Solomon Chih-Cheng Chen; Yueh-Han Hsu
Journal:  J Bone Miner Metab       Date:  2017-12-26       Impact factor: 2.626

2.  Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.

Authors:  Dorte Glintborg; Hanne Mumm; Magda Lambaa Altinok; Bjørn Richelsen; Jens Meldgaard Bruun; Marianne Andersen
Journal:  J Endocrinol Invest       Date:  2014-06-07       Impact factor: 4.256

3.  Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology.

Authors:  Xiaoxia Wang; Renee Chow; Liwen Deng; Dan Anderson; Noel Weidner; Andrew K Godwin; Chanda Bewtra; Albert Zlotnik; Jack Bui; Ajit Varki; Nissi Varki
Journal:  Glycobiology       Date:  2011-04-04       Impact factor: 4.313

4.  Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours.

Authors:  Dorte Glintborg; Magda L Altinok; Kresten R Petersen; Pernille Ravn
Journal:  BMJ Case Rep       Date:  2015-01-23

5.  Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome.

Authors:  Z Kurdoglu; H Ozkol; Y Tuluce; I Koyuncu
Journal:  J Endocrinol Invest       Date:  2011-04-26       Impact factor: 4.256

6.  Association of single-nucleotide polymorphisms rs2197076 and rs2241883 of FABP1 gene with polycystic ovary syndrome.

Authors:  Hongxi Xue; Han Zhao; Xin Liu; Yue-ran Zhao; Zi-Jiang Chen; Jinlong Ma
Journal:  J Assist Reprod Genet       Date:  2015-12-09       Impact factor: 3.412

7.  Association of serum pigment epithelium-derived factor with high-sensitivity C-reactive protein in women with polycystic ovary syndrome.

Authors:  Q Cheng; W Xia; S Yang; P Ye; M Mei; Y Song; M Luo; Q Li
Journal:  J Endocrinol Invest       Date:  2013-09       Impact factor: 4.256

8.  Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial.

Authors:  M Amiri; M Rahmati; M Hedayati; F Nahidi; F Ramezani Tehrani
Journal:  J Endocrinol Invest       Date:  2020-07-17       Impact factor: 4.256

9.  Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome.

Authors:  M Yamamoto; S L Feigenbaum; Y Crites; G J Escobar; J Yang; A Ferrara; J C Lo
Journal:  J Perinatol       Date:  2012-01-19       Impact factor: 2.521

10.  Comparison of metabolic syndrome elements in White and Asian women with polycystic ovary syndrome: results of a regional, American cross-sectional study.

Authors:  Nikhita Chahal; Molly Quinn; Eleni A Jaswa; Chia-Ning Kao; Marcelle I Cedars; Heather G Huddleston
Journal:  F S Rep       Date:  2020-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.